BioVie (id:5386 BIVI)
3.05 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:29:53 AM)
Exchange closed, opens in 1 day 23 hours
-0.65 USD (-0.65%)
-5.28 USD (-5.28%)
162.93 USD (162.93%)
-33.55 USD (-33.55%)
-94.18 USD (-94.18%)
-97.10 USD (-97.10%)
About BioVie
Market Capitalization 59.49M
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
| Headquarters (address) |
680 West Nye Lane Carson City 89703 NV United States |
| Phone | 775 888 3162 |
| Website | https://bioviepharma.com |
| Employees | 14 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | BIVI |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.04 - 56.54 |
| Market Capitalization | 59.49M |
| P/E forward | -0.760 |
| Price/Book | 1.34 |
| Beta | 0.902 |
| EPS | -7.30 |
| EPS United States (ID:6, base:3400) | 24.26 |